Early detection usually offers the best chance to beat cancer. Unfortunately, many tumors aren’t caught until they’ve grown relatively large and spread to other parts of the body. That’s why researchers have worked so tirelessly to develop new and more effective ways of screening for cancer as early as possible. One innovative approach, called “liquid biopsy,” screens for specific molecules that tumors release into the bloodstream.
Recently, an NIH-funded research team reported some encouraging results using a “universal” liquid biopsy called CancerSEEK . By analyzing samples of a person’s blood for eight proteins and segments of 16 genes, CancerSEEK was able to detect most cases of eight different kinds of cancer, including some highly lethal forms—such as pancreatic, ovarian, and liver—that currently lack screening tests.
In a study of 1,005 people known to have one of eight early-stage tumor types, CancerSEEK detected the cancer in blood about 70 percent of the time, which is among the best performances to date for a blood test. Importantly, when CancerSEEK was performed on 812 healthy people without cancer, the test rarely delivered a false-positive result. The test can also be run relatively cheaply, at an estimated cost of less than $500.
Tags: blood test, breast cancer, cancer, cancer blood test, cancer detection, cancer diagnostics, CancerSEEK, clinical study, colorectal cancer, early detection, esophageal cancer, liquid biopsy, liver cancer, lung cancer, machine learning, ovarian cancer, pancreatic cancer, stomach cancer, universal liquid biopsy
After surgically removing a tumor from a cancer patient, doctors like to send off some of the tissue for evaluation by a pathologist to get a better idea of whether the margins are cancer free and to guide further treatment decisions. But for technical reasons, completing the pathology report can take days, much to the frustration of patients and their families. Sometimes the results even require an additional surgical procedure.
Now, NIH-funded researchers have developed a groundbreaking new microscope to help perform the pathology in minutes, not days. How’s that possible? The device works like a scanner for tissues, using a thin sheet of light to capture a series of thin cross sections within a tumor specimen without having to section it with a knife, as is done with conventional pathology. The rapidly acquired 2D “optical sections” are processed by a computer that assembles them into a high-resolution 3D image for immediate analysis.
Tags: 3D imaging, biopsy, breast cancer, cancer, cancer biopsy, cancer diagnostics, cancer imaging, cancer pathology, imaging, light-sheet microscopy, microscopy, pathology, prostate cancer, surgery, tumor scanner
Creative photographers have long experimented with superimposing images, one over the other, to produce striking visual effects. Now a group of NIH-supported scientists at Houston Methodist Research Institute and their colleagues have done the same thing to highlight their work in the emerging field of cancer nanomedicine, using microscopic materials to deliver cancer treatments with potentially greater precision. In the process, the researchers generated a photographic work of art that was a winner in the Federation of American Societies for Experimental Biology 2015 Bioart competition.
The gold cubes are man-made polymer microcarriers, just 2 micrometers wide (by comparison, human cells generally range in diameter from 7 to 20 micrometers), designed to transport chemotherapy drugs directly to tumor cells. These experimental cubes, enlarged in the upper left part of the photo with a scanning electron microscope for better viewing, have been superimposed onto a second photograph snapped with a confocal fluorescence microscope. It shows similar cube-shaped microcarriers (yellow) inside cultured breast cancer cells (nucleus is purple, cytoplasm is turquoise).